Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24558709 | 0.91 | MAP2K1 (0.48) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL24558579 | 0.87 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL24558543 | 0.86 | MAP2K1 (0.54) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL24558537 | 0.84 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL24558699 | 0.84 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL22045811 | 0.82 | MAP2K1 (0.53) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL24558816 | 0.81 | MAP2K1 (0.51) | MAP2K1MAP2K2 | |
| SCHEMBL24558571 | 0.80 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL22045813 | 0.80 | MAP2K1 (0.51) | MAP2K1MEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL22045821 | 0.79 | MAP2K1 (0.52) | MAP2K1MEN1KMT2ATDP1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, NAT1, BRAF | MAP2K1 455/4885MEN1 1581/4885KMT2A 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.